Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 210 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Rejection Transplant Clear all

Conditions: Kidney Transplant Rejection
Interventions: AlloSure; Device
Lead sponsor: CareDx; Industry
Eligibility: 12 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 18
States / cities: Fairfield, California • Fresno, California • Granada Hills, California + 15 more

Conditions: Renal Transplant
Interventions: Campath-1H; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 60 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Kidney Transplant
Interventions: Eculizumab; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Renal Transplant Rejection
Interventions: Prograf, Neoral; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Kidney Transplant Failure and Rejection
Interventions: QSant; Other
Lead sponsor: NephroSant; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Hiv
Interventions: HIV D-/R+; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 18
States / cities: Birmingham, Alabama • Sacramento, California • San Diego, California + 11 more

Conditions: Graft Rejection, Kidney Transplantation
Interventions: plasmapheresis and IVIG, recombinant C1 inhibitor; Procedure · Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Kidney Failure
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
Interventions: Rituximab plus immunosuppression, Placebo plus immunosuppression; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 70 Years
Enrollment: 757 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 17
States / cities: Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 8 more

Conditions: Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions: Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 12
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more

Conditions: Kidney Transplant Rejection
Interventions: MMDx, Prospera, HLA antibody; Diagnostic Test
Lead sponsor: University of Alberta; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 11
States / cities: Tampa, Florida • Baltimore, Maryland • Detroit, Michigan + 5 more

Conditions: Antibody-mediated Rejection
Interventions: Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe; Combination Product · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more

Conditions: Kidney Transplant, Delayed Graft Function
Interventions: Tacrolimus, Sirolimus; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Kidney Transplant
Interventions: Eculizumab; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 70 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Chicago, Illinois • Ithaca, New York • New York, New York + 2 more

Conditions: End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions: Conditioning and Stem cell infusion; Combination Product
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Immunosuppression, Kidney Transplantation, Graft Rejection
Interventions: Infusion of Donor Hematopoietic Stem Cells and Campath-1H; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: End-Stage Renal Disease, Chronic Allograft Nephropathy
Interventions: Irbesartan, Pravastatin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Kidney Transplant Rejection
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Acute Rejection, Renal Transplantation
Interventions: Campath-1H, rituximab, myfortic; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Kidney Transplantation, Renal Transplantation, Grafting, Kidney
Interventions: Envarsus XR, Tacrolimus; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 13 Years to 20 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Kidney Transplant, Chronic Kidney Disease
Interventions: Empagliflozin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 19 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more

Conditions: Kidney Disease, Kidney Failure, End Stage Renal Disease
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more

Conditions: Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Interventions: Daclizumab; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 23
States / cities: Davis, California • Los Angeles, California • Washington D.C., District of Columbia + 19 more

Search by objective public record fields.

Transition of Renal Patients Using AlloSure Into Community Kidney Care

"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant

A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity

Prospective Assessment of Rejection in Kidney Transplant (PARK)

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation

Immune Monitoring in Sensitized Patients at Risk of Rejection

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Trifecta-Kidney cfDNA-MMDx Study

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

HLA-Identical Sibling Renal Transplant Tolerance

Prevention of Kidney Transplant Rejection

The TOGETHER Project - Kidney RNA-seq Validation

Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

Envarsus XR® in Adolescent Renal Transplant Recipients

Empagliflozin Treatment in Kidney Transplant Recipients

A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study

A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients